An Open‐Label, Randomized, 2‐way, Crossover Bioequivalence Study of Cefradine Capsules in Healthy Chinese Volunteers
Xiuping Lai,Suiwen Ye,Liuhan Chen,Junyi Chen,Nan Zhang,Yiwen Zhang,Junyan Wu,Herui Yao
DOI: https://doi.org/10.1002/cpdd.991
2021-01-01
Clinical Pharmacology in Drug Development
Abstract:The purpose of this study was to evaluate whether test cefradine capsules and reference cefradine capsules were bioequivalent in healthy Chinese volunteers. An open-label, randomized, biperiodic, crossover design was used. In each of the 2 study periods (separated by a 1-week washout period), 250-mg single doses of either the test or reference cefradine capsule were administered to study participants under fasted and fed conditions. Blood samples were collected at intervals from predose to 8 hours afterward. In the fasting study, the 90% confidence intervals (90%CI) of the Cmax , AUC0-8h , and AUC0-∞ for the test and reference preparations were 93.7%-112.2%, 94.6%-100.8%, and 94.7%-100.9%, respectively. In the fed study, the 90%CI of the Cmax , AUC0-8h , and AUC0-∞ for the test and reference preparations was 81.0%-99.1%, 100.5%-106.3%, and 100.5%-105.9%, respectively. The results showed that the test cefradine capsules and the reference formulation are bioequivalent under both fasting and fed conditions.